Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
GlaxoSmithKlineNYSE: GSK

GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo

Hengrui PharmaceuticalsNHSA (prev. SMIA)

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

NHC (NHFPC)NHSA (prev. SMIA)

National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector

Chia Tai Tianqing PharmaceuticalCSPC Pharmaceutical

Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent

Show More